Clinical Trials Browser

Phase 1/2 × Interventional × palbociclib × Clear all

NCT03424005 2026-03-16

Morpheus-panBC

Phase 1/2 Recruiting

Breast Neoplasms

NCT04802759 2026-03-16

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Phase 1/2 Recruiting

Neoplasm Metastasis

NCT06736704 2026-03-13

SNV4818 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06843967 2026-03-13

A Study of Mirdametinib in Combination With Palbociclib in People With Liposarcoma

Phase 1/2 Recruiting

Liposarcoma, Liposarcoma, Myxoid

NCT05768139 2026-03-02

PIKALO-1

Phase 1/2 Recruiting

BreastGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06188520 2026-02-24

CYCAD-1

Phase 1/2 Recruiting

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05468697 2026-01-23

MK-6482-024

Phase 1/2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Phase 1/2 Recruiting

Breast Neoplasms

NCT06753747 2025-12-03

A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell Carcinoma

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Neoplasms

NCT03284957 2025-11-24

AMEERA-1

Phase 1/2 Terminated

136 enrolled 60 charts

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03304080 2025-07-18

Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast

Phase 1/2 Active not recruiting

Breast Diseases, Breast Neoplasms

NCT02605486 2025-07-03

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT06947811 2025-06-04

APEAK

Phase 1/2 Recruiting

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

NCT03844997 2025-05-31

Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia

Phase 1/2 Completed

35 enrolled 15 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT06940349 2025-04-23

COPS-01

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumors Refractory to Standard Therapy

NCT06895733 2025-03-26

Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With Co-amplified in the 11q13(FGF3/4/19/CCND1)

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor, Adult

NCT03774472 2025-02-17

Hydroxychloroquine, Palbociclib, and Letrozole Before Surgery in Treating Patients With Estrogen Receptor Positive, HER2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 11 charts

Anatomic Stage I Breast Cancer AJCC v8

NCT05039177 2025-02-11

HERKULES-3

Phase 1/2 Active not recruiting

Gastrointestinal

Digestive System Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT06757335 2025-01-03

A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

Phase 1/2 Not yet recruiting

Breast Neoplasms

NCT04946864 2024-08-19

A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer

Phase 1/2 Suspended

Breast Neoplasms

NCT03560531 2024-08-09

A Study of ZN-c5 in Subjects With Breast Cancer

Phase 1/2 Completed

181 enrolled 36 charts

Breast Neoplasms

NCT03709082 2024-03-05

Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer

Phase 1/2 Terminated

HER2-positive Breast Cancer

NCT04720768 2024-01-05

CELEBRATE

Phase 1/2 Unknown

Melanoma, Neoplasm Metastasis

NCT02101034 2023-12-21

PD 0332991 and Cetuximab in Patients With Incurable SCCHN

Phase 1/2 Completed

96 enrolled 17 charts

Squamous Cell Carcinoma of Head and Neck

NCT03386929 2023-12-18

SPRING

Phase 1/2 Terminated

15 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung

NCT03054363 2023-11-13

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Phase 1/2 Completed

42 enrolled 16 charts

Breast Neoplasms

NCT03158389 2023-09-28

N²M²

Phase 1/2 Completed

Glioblastoma

NCT02448771 2022-10-24

A Study of Palbociclib in Combination With Bazedoxifene in Hormone Receptor Positive Breast Cancer

Phase 1/2 Completed

36 enrolled 28 charts

Breast Neoplasms

NCT03965845 2022-09-19

A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors

Phase 1/2 Completed

Other solid neoplasmThoracic

Solid Tumors

NCT02871791 2022-08-29

Palbociclib With Everolimus + Exemestane In BC

Phase 1/2 Completed

41 enrolled 12 charts

Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

NCT01823835 2021-06-18

A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

Phase 1/2 Terminated

152 enrolled 42 charts

Breast Neoplasms

NCT02349633 2021-06-10

Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)

Phase 1/2 Terminated

65 enrolled 61 charts

Carcinoma, Non-Small-Cell Lung

NCT02202200 2016-04-18

OPTIMUM

Phase 1/2 Unknown

Melanoma